Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data
Abstract Background In January 2021, the United States (US) Food and Drug Administration (FDA) approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen for the treatment of HIV providing an alternative to daily oral regimens. We analyzed electronic health records (EHRs) to...
Saved in:
| Main Authors: | Yiyang Liu, Rebecca J. Fisk-Hoffman, Maitri Patel, Robert L. Cook, Mattia Prosperi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | AIDS Research and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12981-024-00690-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved]
by: Fafa Addo Boateng, et al.
Published: (2025-03-01) -
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study
by: Diana Hernández-Sánchez, et al.
Published: (2025-07-01) -
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics
by: Katerina A. Christopoulos, et al.
Published: (2024-11-01) -
CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation
by: Serena Spampinato, et al.
Published: (2025-06-01) -
The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections
by: Erik De Clercq
Published: (2025-07-01)